Tenderwize
Wróć do wyszukiwania

Open house discount agreements for Rilpivirin depot injection suspension, ATC J05AG05

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 584 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rilpivirin in der Darreichungsform Depot-Injektionssuspension, ATC J05AG05

60/100

Ocena szansy

PromisingLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated contract value or maximum framework amount is provided. It is unclear what volume of business these discou...

The open-house agreements may automatically terminate if a national or regional discount contract for the same product...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Non-exclusive discount agreements for the pharmaceutical product Rilpivirin (ATC J05AG05) in depot injection suspension form.
  • Contracts are offered to all eligible pharmaceutical companies without competition.
Pokaż pełne podsumowanie

This is an open-house model (not a standard procurement procedure) for non-exclusive discount agreements for the pharmaceutical product Rilpivirin in depot injection suspension form (ATC J05AG05). The buyer, AOK Bayern, offers identical, non-negotiable contracts to all interested pharmaceutical companies that meet the eligibility criteria. The early possible start date is 01.06.2026, all contracts end 31.05.2028. Contract conclusion is possible anytime until 03.04.2028. Termination is possible with one month's notice. There is no competition or award selection; any eligible company can join. The estimated value is not provided.

Ryzyka

No estimated contract value or maximum framework amount is provided. It is unclear what volume of business these discou...

The open-house agreements may automatically terminate if a national or regional discount contract for the same product...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contracting partners.
  • Eligibility is proven by a signed self-declaration of reliability (downloadable from the procurement documents).

Administrative

  • Submission must include the signed contract, the signed annex "Determination of the contract medicines", and the signed self-declaration.

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open house discount agreements for Rilpivirin depot injection suspension, ATC J05AG05

Non-exclusive discount agreements for the active substance Rilpivirin in depot injection suspension form. Contracts are identical for all participants. The contract period is from 01.06.2026 to 31.05.2028. Submission deadlines are rolling: to get a contract start on the next month's first day, complete documents must be submitted by the 3rd of the previous month.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

May 2026 - May 2028

Kategoria

Pharmaceutical products

Termin

Deadline Apr 03, 2028

Szczegóły zamówienia

Data publikacji
14 Apr 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
255478-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30